TrialNet Centers Begin Diamyd® Vaccine Study for Recent-Onset Type 1 Diabetes
Diamyd Medical announces today that Type 1 Diabetes TrialNet, a clinical network funded by the National Institutes of Health to prevent and treat newly diagnosed type 1 diabetes, has started recruiting patients for a clinical trial testing the Diamyd®-vaccine’s therapeutic benefit in individuals with recent-onset type 1 diabetes.The study will, as previously announced, assess the vaccine’s ability to protect and preserve insulin-secreting beta cells, which are destroyed by the body’s immune system in type 1 diabetes. Under the terms of the agreement with the National Institute of Diabetes
